JPMorgan Chase & Co. Increases Replimune Group (NASDAQ:REPL) Price Target to $19.00

Replimune Group (NASDAQ:REPL - Free Report) had its price target upped by JPMorgan Chase & Co. from $16.00 to $19.00 in a report released on Wednesday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other research analysts have also weighed in on REPL. Cantor Fitzgerald began coverage on shares of Replimune Group in a report on Friday, June 20th. They set an "overweight" rating for the company. Piper Sandler boosted their target price on shares of Replimune Group from $14.00 to $22.00 and gave the company an "overweight" rating in a research note on Monday, June 2nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price target on shares of Replimune Group in a report on Thursday, July 3rd. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Replimune Group currently has an average rating of "Buy" and a consensus target price of $21.00.

Replimune Group Trading Down 1.1%

NASDAQ:REPL traded down $0.14 on Wednesday, hitting $12.49. 2,248,348 shares of the stock were exchanged, compared to its average volume of 933,780. Replimune Group has a fifty-two week low of $6.44 and a fifty-two week high of $17.00. The stock has a fifty day moving average of $9.34 and a 200-day moving average of $10.49. The company has a current ratio of 7.95, a quick ratio of 7.95 and a debt-to-equity ratio of 0.17. The stock has a market cap of $963.09 million, a PE ratio of -4.09 and a beta of 0.61.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter last year, the business posted ($0.25) earnings per share. As a group, equities analysts expect that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Konstantinos Xynos sold 7,952 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $64,093.12. Following the completion of the sale, the insider owned 146,933 shares in the company, valued at approximately $1,184,279.98. This represents a 5.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Philip Astley-Sparke sold 32,279 shares of the company's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $260,168.74. Following the transaction, the director directly owned 1,405,071 shares in the company, valued at $11,324,872.26. The trade was a 2.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 74,907 shares of company stock valued at $603,655 in the last three months. Insiders own 8.80% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD grew its holdings in shares of Replimune Group by 11.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock valued at $132,761,000 after acquiring an additional 1,083,633 shares in the last quarter. Redmile Group LLC grew its stake in Replimune Group by 2.6% in the fourth quarter. Redmile Group LLC now owns 4,905,527 shares of the company's stock valued at $59,406,000 after purchasing an additional 124,344 shares in the last quarter. Vanguard Group Inc. grew its stake in Replimune Group by 6.6% in the first quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company's stock valued at $37,372,000 after purchasing an additional 237,185 shares in the last quarter. Tang Capital Management LLC increased its position in Replimune Group by 125.0% in the 4th quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock worth $32,697,000 after purchasing an additional 1,500,000 shares during the last quarter. Finally, RTW Investments LP raised its stake in shares of Replimune Group by 82.1% during the 4th quarter. RTW Investments LP now owns 2,065,010 shares of the company's stock worth $25,007,000 after purchasing an additional 931,223 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.